CEL-SCI (CVM): Prakiraan rega marang bathi
A dedicated team of veteran scientists established the foundation of CEL-SCI Corporation (CVM). The company's expected P/E trend reflects current market dynamics, where 0.00 represents the latest level. Prospects depend on the success of Multikine and FDA decisions, as well as the implementation of eco-friendly chemical waste recycling systems within the laboratories.
Rincian metrik lan analitis perusahaan CEL-SCI Corp (CVM)
- kuotasi lan prakiraan analis:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal CEL-SCI Corporation|CVM - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal CEL-SCI Corporation|CVM - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku CEL-SCI Corp.|CVM - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan CEL-SCI|Likuiditas cepet cel-sci.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
CVM - Asil keuangan resik|Proyeksi bathi mangsa ngarep CEL-SCI Corporation|CVM - Koefisien rega marang bathi|Pangali Forward P/E CEL-SCI Corporation|CVM - Kapitalisasi marang bathi resik kanthi nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan CEL-SCI Corp.|CVM - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) CEL-SCI|CVM - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan cel-sci.com|CVM - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep CEL-SCI Corporation
- informasi babagan volume dodolan lan pendapatan:
Analisis kabeh metrik perusahaan:CVM CEL-SCI
CEL-SCI Corporation operations are constrained by a critical shortage of funds and capital dilution risks, making the company's 12-month forward P/E analysis a key tool for assessing business viability. This indicator compares the issuer's current market value with projected net income, allowing investors to determine the extent of the asset's overvaluation amid the uncertainty of clinical approvals.
Perusahaan pesaing
Pangali Forward P/E ONC|Prakiraan rega marang bathi Halozyme Therapeutics, Inc. HALO|RevMed - Prakiraan rega marang bathi|Pangali Forward P/E Ascentage Pharma Corp AAPG|CGON - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi URGN (urogen.com)|BCAX: Pangali Forward P/E|Rasio prakiraan rega marang bathi Personalis Inc (PSNL)|ERAS (Erasca Corp) - Pangali Forward P/E|Prakiraan rega marang bathi Delcath Corp (DCTH)|Pangali Forward P/E YMAB|AURA - Rasio prakiraan rega marang bathi|Rega marang bathi mangsa ngarep Candel Therapeutics, Inc. CADL|Accuray Inc - Rega marang bathi mangsa ngarep|SLS: Prakiraan rega marang bathi|Pangali forward rega marang bathi Actuate Therapeutics Inc (ACTU)|Citius Oncology, Inc. (CTOR) - Rega marang bathi mangsa ngarep|HURA - Kapitalisasi marang proyeksi bathi|TARA (Protara Therapeutics, Inc.) - Pangali Forward P/E|Prakiraan rega marang bathi Fate Therapeutics Inc (FATE)|Pangali Forward P/E WHWK|Kapitalisasi marang proyeksi bathi tscan.com|Champions Oncology, Inc. - Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi XBIT|OS Therapies - Pangali Forward P/E|radiopharmtheranostics.com (RADX) - Prakiraan rega marang bathi|artivabio.com (ARTV) - Rega marang bathi mangsa ngarep|Rasio prakiraan rega marang bathi Adlai Nortye (ANL)|Rega marang bathi mangsa ngarep Veru Inc.|TPST: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Xilio Therapeutics, Inc. (XLO)|RENB: Rasio rega marang bathi sing dikarepake|Rega marang bathi mangsa ngarep Mural Oncology MURA|Kairos Pharma Limited (KAPA) - Rasio prakiraan rega marang bathi|OKUR - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi GDTC (CytoMed Therapeutics)|CRIS: Pangali Forward P/E|Apollomics (APLM) - Pangali Forward P/E|Prakiraan rega marang bathi THAR|ADVB (Advanced Biomed Corp) - Rasio kapitalisasi marang bathi mangsa ngarep|Pangali Forward P/E GNPX|Kapitalisasi marang proyeksi bathi calidibio.com|Rega marang bathi mangsa ngarep Sunshine Biopharma, Inc. SBFM|Xenetic Biosciences Inc. (XBIO) - Rasio prakiraan rega marang bathi|SLRX - Rega marang bathi mangsa ngarep|PPBT (Kitov Pharma) - Rasio rega marang bathi mangsa ngarep|AONC: Pangali Forward P/E|Prakiraan rega marang bathi beigene.com|Prakiraan rega marang bathi CKPT|Rega marang bathi mangsa ngarep ELEV|Rega marang bathi mangsa ngarep iCAD, Inc. (ICAD)|Prakiraan rega marang bathi ikenaoncology.com IKNA|Pangali Forward P/E NTBL (Notable Labs, Ltd.)|VIRX - Prakiraan rega marang bathi|MorphoSys - Pangali Forward P/E|NAYA - Pangali Forward P/E|Ascentage Pharma Group Ltd (AAPGV) - Rega marang bathi mangsa ngarep
